Saturday, August 02, 2014 8:38:49 AM
Selling of size erodes demand for the stock, even if it's done carefully and only temporary. If they choose to short at the same time the company sells they have weaker support to chew through. My guess is that if you compare those sales you will see dumpage, but it will be out of proportion with the legitimate selling that was done because of that.
An example of how wicked these dudes are - we found our that the reasonably priced PR service we were using was manned by ex-Big Apple employee, Fairhills associate, and enemy of the company Elliott Poloatoff. They were leaking our PR's to the hedgies as soon as we filed them. When the people holding our debt stock tried to sell the P&D orders were all ready set up. One morning an investor's account was mysteriously locked up and he couldn't sell until the price went down. This is how they try to keep small companies from raising any money on the market - they get theirs first.
The SEC does nothing about them. Polatoff was associated with Fairhills capital, their computers were seized in an FBI raid as year or two ago and we've heard nothing on prosecution. Big Apple criminals have moved on to new companies and new scams and nothing has been done to stop them.
SEC action on Polatoff - note the date and the slap on the wrist:
http://www.linkedin.com/pub/elliott-polatoff/2a/5a9/744
Slap on the wrist from FINRA
Elliott Steven Polatoff (CRD #1956658, Registered Representative, Far Rockaway, New York) submitted a Letter of Acceptance, Waiver, and Consent in which he was fined $13,000, suspended from association with any NASD member in any capacity for three months, and required to pay $1,856.25, plus interest, in restitution to member firms. Payment of the fine and proof of payment of restitution shall be prerequisites before reassociating with any NASD member or before requesting relief from any statutory disqualification. Without admitting or denying the allegations, Polatoff consented to the described sanctions and to the entry of findings that he knowingly and intentionally entered priced limit orders in Nasdaq securities into an electronic communications network (ECN) at prices that he knew would improve the national best bid or offer (NBBO) in such securities, in that the full price and size of such orders would be reflected in the public quotation system as the best prices and sizes at which a market participant was willing to buy or sell such securities. Furthermore, the NASD found that after entering such orders, Polatoff entered orders of such securities in his trading account because he knew that they would be routed to market makers whose automated execution systems were programmed to transact such securities on an automated basis at prices equal to the NBBO and in an amount greater than the NBBO, thereby enabling him to buy and sell shares of the securities at prices that were lower or higher than he would otherwise have been able to buy or sell shares of the securities. Moreover, the findings stated that immediately after he received the executions of the orders that he had entered in his trading account, Polatoff canceled priced limit orders that he had entered into the ECN.
Polatoff's suspension began January 7, 2002, and will conclude at the close of business April 5, 2002. (NASD Case #CMS010172)
http://finra.complinet.com/en/display/viewall_display.html?rbid=1189&element_id=1159002724&record_id=1159002800
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM

